NCT02859259View on ClinicalTrials.gov

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 12, 2016

Primary Completion Date

August 12, 2016

Study Completion Date

August 12, 2016

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

BMS-663068 (1 tablet at 600 mg)

BMS-663068 (1 tablet at 600 mg). A single dose of BMS-663068 administered orally as specified.

DRUG

BMS-663068 (4 tablets at 150 mg each tablet)

BMS-663068 (4 tablets at 150 mg each tablet). A single dose (4 tablets) of BMS-663068 administered orally as specified.

Trial Locations (1)

75247

GSK Investigational Site, Dallas

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY

NCT02859259 - A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects | Biotech Hunter | Biotech Hunter